OBESITY - 206 Annonces

Friday 01 August 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 01 August 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Thursday 31 July 2025

Quantité : 1kg; 25kg;

5-hydroxytryptophan is a dietary supplement made from the seeds of the African plant Griffonia simplicifolia. 5-hydroxytryptophan has been used in alternative medicine as a possibly effective aid in treating depression or fibromyalgia. Other uses not proven with research have included insomnia...

Thursday 31 July 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 60mg*10via - Prix : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 50mg*10via - Prix : USD 550

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 40mg*10via - Prix : USD 450

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 30mg*10via - Prix : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 29 July 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 26 July 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 26 July 2025

Quantité : 1kg; 25kg;

GIP is widely used in studying insulin secretion mechanisms, lipid metabolism, and the pathophysiology of diabetes and obesity. GIP and its receptor agonists are being studied for the treatment of type 2 diabetes and obesity. Brand: Soarwin Localisation : Chongqing, 401102 Chongqing...

Saturday 26 July 2025

Quantité : 1kg; 25kg;

Beta-Diphosphopyridine nucleotide (β-DPN) was discovered in the mid-20th century during research into cellular metabolism and energy production. Its identification stemmed from investigations into the role of coenzymes in biochemical reactions, particularly those involved in oxidative...

Friday 25 July 2025

Quantité : 1kg; 25kg;

Nicotinamide ribonucleotide (NMN) is a nucleotide derived from ribose and nicotinamide, a form of vitamin B3. The discovery of NMN dates back to early studies on the biosynthesis of nicotinamide adenine dinucleotide (NAD+), a crucial coenzyme in cellular metabolism. Researchers identified...

Friday 25 July 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Friday 25 July 2025

Quantité : 60mg*10via - Prix : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 50mg*10via - Prix : USD 550

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 40mg*10via - Prix : USD 450

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 30mg*10via - Prix : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 25 July 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 22 July 2025

Understanding the role of β-DPN in cellular metabolism is essential for the development of therapeutics targeting metabolic diseases. Pharmaceutical companies utilize β-DPN as a target for drug discovery and development, aiming to modulate its activity to treat conditions like diabetes...

Saturday 19 July 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...